Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.

Patz, Edward F.; Lowe, Val J.; Hoffman, John M.; Paine, Susan; Harris, Laura; Goodman, Philip C.

doi:10.1148/radiology.191.2.8153309

Cited by 191 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have evaluated the role of FDG PET for staging lung carcinoma. Most investigators have used focal techniques and concentrated on mediastinal lymph node staging [5][6][7][8][9]. Concerning the detection of distant metastases by whole-body FDG PET, three studies have already been published showing that the technique has excellent accuracy [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

“…This uptake can be used in PET studies to visualize the tumour with high contrast compared with the surrounding tissue [2][3][4]. Considerable experience is now available on the diagnostic value of FDG PET in the mediastinal staging of lung cancer [5][6][7][8][9] but analysis of the efficiency of FDG PET for the detection of distant metastasis remains fragmentary [10][11][12]. This paper reports our current clinical experience in 110 patients with nonsmall cell lung cancer (NSCLC).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

Bury

Barreto

Daenen

et al. 1998

European Journal of Nuclear Medicine and Molecular Imaging

283

View full text Add to dashboard Cite

Abstract. Despite advances in morphological imaging, some patients with lung cancer are found to have non resectable disease at surgery or die of recurrence within a year of surgery. At present, metastatic bone involvement is usually assessed using bone scintigraphy, which has a high sensitivity but a poor specificity. We have attempted to evaluate the utility of the fluorine-18 deoxyglucose positron emission tomography (FDG PET) for the detection of bone metastasis. One hundred and ten consecutive patients with histological diagnosis of non-small cell lung cancer (NSCLC) who underwent both FDG PET and bone scintigraphy were selected for this review. In this group, there were 43 patients with metastatic disease (stage IV). Among these, 21 (19% of total group) had one or several bone metastases confirmed by biopsy (n = 8) or radiographic techniques (n = 13). Radionuclide bone scanning correctly identified 54 out of 89 cases without osseous involvement and 19 out of 21 osseous involvements. On the other hand, FDG PET correctly identified the absence of osseous involvement in 87 out of 89 patients and the presence of bone metastasis in 19 out of 21 patients. Thus using PET there were two false-negative and two false-positive cases. PET and bone scanning had, respectively, an accuracy of 96% and 66% in the evaluation of osseous involvement in patients with NSCLC. In conclusion, our data suggest that whole-body FDG PET may be useful in detecting bone metastases in patients with known NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

Bury

Barreto

Daenen

et al. 1998

European Journal of Nuclear Medicine and Molecular Imaging

283

View full text Add to dashboard Cite

show abstract

“…These studies must be separated into two groups, Some investigators have used focal techniques and have concentrated on hilar and mediastinal lymph node staging, while others have used whole-body techniques and have evaluated extrathoracic (Table 2) [49,[110][111][112][113][114][115][116][117][118][119]. The reported sensitivity for lymph node staging in non-small cell lung cancer varies from 82% to 100% and the specificity from 73% to 100%.…”

Section: Fig 2 Malignant Solitary Pulmonary Nodule (Adenosquamous Cmentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

“…Data from a recent publication indicate that current RECIST criteria may have positive predictive value as low as 28%, leading to a high number of false positive results [10] . Incorporating additional anatomic and metabolic imaging data, although not 100% specific, may help to improve the diagnostic accuracy of recurrences [10][11][12][13] .…”

Section: Discussionmentioning

confidence: 99%

Evaluating patterns of failure and salvage therapy for patients treated with primary stereotactic body radiation therapy for early stage non-small cell lung cancer

Mezera

Chandrasekhar

Kloecker

et al. 2014

JST

View full text Add to dashboard Cite

Objective: The purpose of this study is to evaluate patterns of failure after stereotactic body radiation therapy for early stage NSCLC and determine the role of salvage therapy on patient outcome.Methods: Eighty-two consecutive medically inoperable patients treated with definitive SBRT for early-stage NSCLC were examined. Ninety-four percent of patients had biopsy proven disease, the remainder refused. The median biologic effective dose (BED) for the cohort was 100 Gy (range, 78-180 Gy). Recurrence was defined clinically by RECIST and FDG-PET or by pathologic diagnosis. Results:The estimated median survival for the entire cohort was 29.2 months (range, 1 -40.3). The estimated 2 year overall survival (OS) was 65%. The 2 year local recurrence free survival, locoregional recurrence free survival and distant metastatic free survival were 89%, 78% and 72%, respectively. Of those with locoregional failure, ten were treated with salvage SBRT at a median time of 10 months from prior SBRT. Six patients were treated with systemic chemotherapy and 2 patients were offered palliative care. All patients treated with salvage SBRT remained controlled at a median time of 12 months. Treatment was well tolerated with 2 patients experiencing grade 2 pneumonitis, 1 patient experiencing grade 3 chest wall pain and 1 with rib fracture. OS was compared between 3 subgroups: no locoregional failure (n = 65), locoregional failure without SBRT salvage (n = 7) and locoregional failure with SBRT salvage (n = 10). The estimated median survival 31.3 months, 14.3 months and 29.9 months, respectively (p = 0.007). Conclusion:In our single institution patient cohort, SBRT in the salvage setting for locoregional recurrences after initial definitive SBRT for early-stage NSCLC is a potential option. Additional prospective data is needed.

show abstract

Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.

Abstract: FDG PET accurately helps differentiate recurrent bronchogenic carcinoma from fibrosis.

Cited by 191 publications

References 0 publications

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Evaluating patterns of failure and salvage therapy for patients treated with primary stereotactic body radiation therapy for early stage non-small cell lung cancer

Contact Info

Product

Resources

About